Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling  Baoping Cao, MD, PhD, Weili Yang,

Slides:



Advertisements
Similar presentations
Volume 342, Issue 1, Pages (January 2014)
Advertisements

Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer  Yong-Jae Kwon, PhD, Seog Joo Lee, MSc, Jae Soo Koh, MD, PhD, Sung.
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Cell Physiol Biochem 2015;36: DOI: /
Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.
Volume 135, Issue 1, Pages e3 (July 2008)
PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors
Integrin αvβ6 Promotes Lung Cancer Proliferation and Metastasis through Upregulation of IL-8–Mediated MAPK/ERK Signaling  Pengwei Yan, Huanfeng Zhu, Li.
WT1 Promotes Invasion of NSCLC via Suppression of CDH1
Volume 143, Issue 3, Pages e2 (September 2012)
Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis  Ruo-Chia Tseng, PhD, Jia-Ming Chang,
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo  Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.
Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer  Yong-Jae Kwon, PhD, Seog Joo Lee, MSc, Jae Soo Koh, MD, PhD, Sung.
Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT  Zhen-Yu He, San-Gang Wu, Fang Peng,
ITPKA Gene Body Methylation Regulates Gene Expression and Serves as an Early Diagnostic Marker in Lung and Other Cancers  Yi-Wei Wang, PhD, Xiaotu Ma,
Volume 136, Issue 2, Pages e1 (February 2009)
MicroRNA-489 Plays an Anti-Metastatic Role in Human Hepatocellular Carcinoma by Targeting Matrix Metalloproteinase-7  Yixiong Lin, Jianjun Liu, Yuqi Huang,
Volume 143, Issue 3, Pages e12 (September 2012)
WNT5A is epigenetically silenced in hematologic malignancies and inhibits leukemia cell growth as a tumor suppressor by Jianming Ying, Hongyu Li, Yun-Wen.
Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
TGM2: A Cell Surface Marker in Esophageal Adenocarcinomas
Volume 146, Issue 7, Pages e5 (June 2014)
P63 and p73 Isoform Expression in Non-small Cell Lung Cancer and Corresponding Morphological Normal Lung Tissue  Marco Lo Iacono, PhD, Valentina Monica,
Epigenetic Inhibition of Nuclear Receptor Small Heterodimer Partner Is Associated With and Regulates Hepatocellular Carcinoma Growth  Nan He, Kyungtae.
Interleukin-17 and Prostaglandin E2 Are Involved in Formation of an M2 Macrophage- Dominant Microenvironment in Lung Cancer  Lunxu Liu, MD, PhD, Dongxia.
Volume 129, Issue 1, Pages (July 2005)
Teruaki Fujishita, Masahiro Aoki, Makoto M. Taketo  Gastroenterology 
Aldehyde Dehydrogenase 1A1 Possesses Stem-Like Properties and Predicts Lung Cancer Patient Outcome  Xiao Li, MD, Liyan Wan, MD, Jian Geng, MD, Chin-Lee.
Molecular Therapy - Nucleic Acids
Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma
The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth  Lars Henning Schmidt,
Volume 145, Issue 2, Pages e6 (August 2013)
Pulmonary Fibroblasts Induce Epithelial Mesenchymal Transition and Some Characteristics of Stem Cells in Non-Small Cell Lung Cancer  Yasushi Shintani,
Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer  Gengpeng Lin, MD, Longhua Sun,
MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity 
Activated Leukocyte Cell-Adhesion Molecule (ALCAM) Promotes Malignant Phenotypes of Malignant Mesothelioma  Futoshi Ishiguro, MD, Hideki Murakami, MD,
Yuen Yee Cheng, PhD, Michaela B
Chandra Goparaju, PhD, Jessica S
Frequent Coamplification and Cooperation between C-MYC and PVT1 Oncogenes Promote Malignant Pleural Mesothelioma  Erick Riquelme, PhD, Milind B. Suraokar,
Volume 144, Issue 5, Pages e4 (May 2013)
Volume 133, Issue 6, Pages (December 2007)
Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.
The Hematopoietic Stem Cell Regulatory Gene Latexin Has Tumor-Suppressive Properties in Malignant Melanoma  Viswanathan Muthusamy, Sanjay Premi, Cara.
Ying-Ying Yu, Ph. D. , Cui-Xiang Sun, Ph. D. , Yin-Kun Liu, Ph. D
P16Ink4a Suppression of Lung Adenocarcinoma by Bmi-1 in the Presence of p38 Activation  Mi-Ok Lee, MSc, Hyeon-Jae Lee, MD, Mi-Ae Kim, MD, Eun-Kyung Kim,
Molecular Therapy - Nucleic Acids
Volume 25, Issue 3, Pages (March 2017)
MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2  Ji-guang Zhang,
SOX4 Promotes Proliferative Signals by Regulating Glycolysis through AKT Activation in Melanoma Cells  Wei Dai, Xinyuan Xu, Shuli Li, Jingjing Ma, Qiong.
Volume 142, Issue 7, Pages e2 (June 2012)
IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling  Yasushi.
Human Mitochondrial NAD(P)+–Dependent Malic Enzyme Participates in Cutaneous Melanoma Progression and Invasion  Yung-Lung Chang, Hong-Wei Gao, Chien-Ping.
MiR-205 and MiR-375 MicroRNA Assays to Distinguish Squamous Cell Carcinoma from Adenocarcinoma in Lung Cancer Biopsies  Santosh Patnaik, MD, PhD, Reema.
Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma  Soonyean Hwang, Hye-Eun Kim, Michelle Min, Rekha.
Inhibition of SOX17 by MicroRNA 141 and Methylation Activates the WNT Signaling Pathway in Esophageal Cancer  Yan Jia, Yunsheng Yang, Qimin Zhan, Malcolm.
A LIN28B Tumor-Specific Transcript in Cancer
Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation 
Core promoter methylation in mediators of adipogenesis.
Figure 1. RSPO3 expression is upregulated in bladder cancer
Volume 36, Issue 2, Pages (October 2009)
The human GPR109A promoter is methylated and GPR109A expression is silenced in human colon carcinoma cells. The human GPR109A promoter is methylated and.
Long Noncoding RNA BC as a Novel Therapeutic Target for Colorectal Cancer that Suppresses Metastasis by Upregulating TIMP3  Jiaxin Lin, Xin Tan,
MET Increases the Sensitivity of Gefitinib-Resistant Cells to SN-38, an Active Metabolite of Irinotecan, by Up-Regulating the Topoisomerase I Activity 
HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib
The lncRNA PDIA3P Interacts with miR-185-5p to Modulate Oral Squamous Cell Carcinoma Progression by Targeting Cyclin D2  Cheng-Cao Sun, Ling Zhang, Guang.
The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI  Feng Xing, Shuo Wang, Jianhong Zhou  Molecular.
Overexpression of Muscarinic Receptor 3 Promotes Metastasis and Predicts Poor Prognosis in Non–Small-Cell Lung Cancer  Gengpeng Lin, MD, Longhua Sun,
Presentation transcript:

Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling  Baoping Cao, MD, PhD, Weili Yang, MD, Yongshuai Jin, MD, Meiying Zhang, MS, Tao He, MD, Qimin Zhan, MD, James G. Herman, MD, Guanglin Zhong, MD, Mingzhou Guo, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 11, Pages 1912-1926 (November 2016) DOI: 10.1016/j.jtho.2016.06.015 Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 1 The expression and methylation status of naked cuticle homolog 2 (NKD2) in esophageal cancer cells and normal esophageal mucosa (NE). (A) Semiquantitative reverse-transcriptase polymerase chain reaction (RT-PCR) shows NKD2 expression levels in esophageal cancer cell lines. KYSE450, KYSE30, KYSE150, KESE70, TE8, KYSE410, TE1, KYSE140, and COLO680 are esophageal cancer cell lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the internal control of RT-PCR. H2O is double-distilled water. Minus sign indicates absence of 5-aza-2′-deoxycytidine (5-AZA) and plus sign indicates presence of 5-AZA. (B) Methylation-specific polymerase chain reaction (MSP) results of NKD2 in esophageal cancer cell lines. U refers to unmethylated alleles, and M refers to methylated alleles. In vitro methylated DNA (IVD) serves as a methylation control; normal peripheral lymphocyte DNA (NL) serves as an unmethylation control. H2O is double-distilled water. (C) Bisulfite sequencing (BSSQ) results of NKD2. KYSE150, KYSE410, TE1, and KYSE450 are esophageal cancer cells. Double-headed arrow indicaets that the MSP PCR product spanned 103 base pairs (bp) in NKD2. Bisulfite sequencing focused on a 287-bp region of the CpG island (–287 bp to +38 bp) across the NKD2 transcription start site (TSS). Filled circles are methylated CpG sites, and open circles are unmethylated CpG sites. Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 2 Methylation status and expression of naked cuticle homolog 2 (NKD2) in primary esophageal cancer samples. (A) Methylation-specific polymerase chain reaction (MSP) results of NKD2 in normal esophageal mucosa (NE). (B) Representative results of MSP for NKD2 in primary esophageal cancer samples (EC). (C) Representative immunohistochemical analysis results showing NKD2 expression in esophageal cancer and matched adjacent tissue samples (upper images: ×100; lower images: ×400). (D) NKD2 expression scores are shown as box plots, with horizontal lines representing the median score; the bottom and top of the boxes represent the 25th and 75th percentiles, respectively, and vertical bars represent the range of data. The expression level of NKD2 was significantly different between adjacent tissue and esophageal cancer samples (***p < 0.001). (E) The bar diagram shows the expression and DNA methylation status of NKD2 in different cancer samples. Reduced expression of NKD2 was significantly associated with promoter region methylation (**p < 0.01). Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 3 Naked cuticle homolog 2 (NKD2) inhibits esophageal cancer cell proliferation. (A) Growth curves represent the cell viability analyzed by the methyl thiazolyl tetrazolium assay in KYSE150 and TE1 cells in which NKD2 was reexpressed and unexpressed. The experiments were performed in triplicate (*p < 0.05 and ***p < 0.001). (B) Colony formation results show that colony number was reduced by reexpression of NKD2 in KYSE150 and TE1 cells. Each experiment was repeated three times. The average number of tumor clones is represented by a bar diagram (***p < 0.001). (C) Cell phase distribution in KYSE150 and TE1 cells in which NKD2 was unexpressed and reexpressed. The ratio is presented by a bar diagram. Each experiment was repeated three times (**p < 0.01 and ***p < 0.001). G0/G1, G0/G1 phase; S, S phase; G2/M, G2/M phase. Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 4 Restoration of naked cuticle homolog 2 (NKD2) expression inhibits cell migration and invasion. (A) Cell migration in KYSE150 and TE1 cells in which NKD2 was unexpressed and reexpressed. The ratio is presented by a bar diagram. Each experiment was repeated three times (***p < 0.001). (B) Cell invasion in KYSE150 and TE1 cells in which NKD2 was unexpressed and reexpressed. The ratio is presented by a bar diagram. Each experiment was repeated three times (***p < 0.001). (C) The expression levels of NKD2, matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-7 (MMP-7), and matrix metalloproteinase-9 (MMP-9) were detected by Western blot in KYSE150 and TE1 cells in which NKD2 was unexpressed and reexpressed. Knockdown of NKD2 by small interfering RNA (siRNA) was performed to validate the results in KYSE450 cells in which NKD2 was highly expressed. (D) Representative images of immunohistochemical analysis for NKD2, MMP2, and MMP9 in human esophageal squamous cell cancer. The expression levels of NKD2, MMP2, and MMP9 were evaluated by the German semiquantitative scoring system. The correlation of NKD2 and MMP2, or NKD2 and MMP9, was analyzed by Pearson correlation coefficient. The x axis represents levels of NKD2 and the y axis represents levels of MMP2 or MMP9. NC, KYSE450 cells in which NKD2 is highly expressed; SiNKD2, KYSE450 cells in which NKD2 is knocked down by siRNA. Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 5 Naked cuticle homolog 2 (NKD2) inhibits canonical Wnt signaling in human esophageal cancer cells. (A) The expression levels of β-catenin, cyclin D1, and c-myc were reduced, and the level of phosphorylated β-catenin (p-β-catenin) increased after reexpression of NKD2 in KYSE150 and TE1 cells. (B) The level of p-β-catenin was reduced and the expression levels of β-catenin, c-myc, and cyclin D1 increased after knockdown of NKD2 by small interfering RNA (siRNA) in KYSE450 cells. (C) Representative images of immunohistochemical analysis for NKD2 and phosphorylated β-catenin (p-β-catenin) in human esophageal squamous cell cancer. The expression levels of NKD2 and p-β-catenin were evaluated by the German semiquantitative scoring system. The correlation of NKD2 and p-β-catenin was analyzed with Pearson's correlation coefficient. The x axis represents levels of NKD2, and the y axis represents levels of p-β-catenin. NC, KYSE450 cells in which NKD2 is highly expressed; SiNKD2, KYSE450 cells in which NKD2 has been knocked down by siRNA. Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Figure 6 Naked cuticle homolog 2 (NKD2) suppresses esophageal cancer cell growth in xenograft mice. (A) Representative burdened nude mice with NKD2 reexpressed and unexpressed in KYSE150 cells and NKD2 expressed and knocked down in KYSE450 cells. The tumor locations are shown by red arrowhead. (B) Subcutaneous tumor growth curves for xenograft mice burdened with KYSE150 cells in which NKD2 is unexpressed and reexpressed and KYSE450 cells is which NKD2 is expressed and knocked down at different times (***p < 0.001). (C) Tumor weight in nude mice at the 24th day after inoculation with KYSE150 cells in which NKD2 is unexpressed and reexpressed and KYSE450 cells in which NKD2 is expressed and knocked down. Bars indicate mean of six mice (***p < 0.001). (D) Representative photographs of immunohistochemical analysis for NKD2, β-catenin, and p-β-catenin in xenografts. Staining of NKD2 and p-β-catenin was found in KYSE150 cell xenografts in which NKD2 is reexpressed. Staining of total β-catenin was reduced in KYSE150 cell xenografts in which NKD2 is reexpressed. Magnification: ×400. NC, KYSE450 cells in which NKD2 is highly expressed; SiNKD2, KYSE450 cells in which NKD2 has been knocked down by small interfering RNA. Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 1 Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 2 Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Supplementary Figure 3 Journal of Thoracic Oncology 2016 11, 1912-1926DOI: (10.1016/j.jtho.2016.06.015) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions